Research

Data Aims to Help Pharma Firms Pinpoint Repositioning Potential

Information from Thomson Reuters is designed to help drug companies locate drugs with repositioning potential, in order to increase profitability.

With more than 2,000 drugs reintroduced for alternative purposes to date, drug repositioning has become a viable solution for pharmaceutical companies to generate additional revenue. The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, provided deeper insight today into the unique approach its Life Sciences consulting service takes in analyzing drugs and drug candidates to identify those with potential for repositioning.

No votes yet

Study: Credentialed Foreign Online Pharmacies are Safe to Use

One agency’s research contradicts figures from the FDA stating that patients using the companies are at risk of receiving ineffective or dangerous products.

Are non-U.S. online pharmacies safe to use? The U.S. Food and Drug Administration would like you to think they are not, but independent research continues to show that they are. New data published by the National Bureau of Economic Research (NBER) found that medication ordered from credentialed online pharmacies, foreign or domestic, was genuine and safe. Only non-credentialed pharmacies sold products which were not genuine. The main difference between credentialed foreign and domestic pharmacies was price: Non-U.S. pharmacies sold the same drugs at an average 51% discount.

Your rating: None Average: 1 (1 vote)

Agilent, Molecular Discovery Partner on Drug Development

The two companies have joined forces to provide researchers with an advanced metabolite-identification platform.

Agilent Technologies Inc. today announced that it has entered into a comarketing agreement with Molecular Discovery Ltd. to provide biopharmaceutical researchers with an advanced metabolite-identification platform. The companies will comarket the combined assets of Agilent's high-resolution liquid chromatography/mass spectrometry (LC/MS) technology and Molecular Discovery's Mass-MetaSite software to enable superior identification and analysis of complex biological mixtures.

No votes yet

Omeros Announces Unlocking of Class A Orphan GPCRs

The unlocking of the compounds, according to the company, could lead to new treatments for autism, osteoarthritis neuropsychiatric disorders.

Omeros Corp. announced that it has identified compounds that functionally interact with each of five additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 42 Class A orphan GPCRs, representing over half of these targets. There are approximately 120 orphan GPCRs and Omeros expects to unlock a large percentage of them, focusing first on Class A orphans.

No votes yet

Study: Patients Struggle to Control Multiple Chronic Conditions

Research by Kaiser Permanente shows that people with diabetes, high blood pressure, and high cholesterol have difficultly managing the conditions.

Most people who have diabetes, high blood pressure, and high cholesterol have difficultly managing all three conditions; indeed, success is fleeting for those who do manage all three, according to a Kaiser Permanente Institute for Health Research study that appears online in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

No votes yet

BioClinica, C.R. Bard Win 2012 Microsoft Life Sciences Innovation Award

The companies have been saluted for efforts to help bring treatments to the market faster.

BioClinica Inc., a global provider of clinical trial management solutions, announced that it is, together with C.R. Bard, a 2012 winner of Microsoft Corporation’s prestigious Life Sciences Innovation Award. The awards, announced at the Drug Information Association’s (DIA) 48th Annual Meeting in Philadelphia, honor companies that use Microsoft solutions to realize business and information technology benefits.

No votes yet

Simulations Plus Partners on Oral-Cavity Dosing Model

The software firm is working with a pharmaceutical firm to develop ths model in its GastroPlus simulation software.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a collaboration agreement with a top-5 pharmaceutical company to extend and enhance its oral cavity dosing model within its industry gold standard GastroPlus™ simulation software program.

No votes yet

Major Drug Firms to Collaborate on Research

The Battelle Drug Discovery CoLaborative is designed to bring big pharmaceutical and biotech firms together to bring new drugs to market more quickly.

Battelle, a global leader in health care research and development, unveiled a unique and innovative collaboration model that will enhance the efficiency of the pharmaceutical industry's drug discovery efforts.

No votes yet

Advanced Cancer Therapies on the Rise

Research indicates a recent sharp increase of efforts to develop smart drugs, gene therapies and other high-tech treatments.

New research shows a sharp escalation in the weapons race against cancer, with several high-tech approaches long dreamed of but not possible or successful until now.

At a weekend conference of more than 30,000 cancer specialists, scientists reported:

—New "smart" drugs that deliver powerful poisons directly to cancer cells while leaving healthy ones alone.

—A new tool that helps the immune system attack a broad range of cancer types.

No votes yet

Roche's RoACTEMRA Reportedly Improves RA Signs, Symptoms

Recent study data shows that the rheumatoid arthritis drug demonstrates more successful results than adalimumab as a single-agent therapy.

Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy

No votes yet
Syndicate content